Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer.
McCracken will be responsible for leading all commercial activities, driving revenue growth in new and existing markets and expanding the company’s global reach. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, McCracken will advance Fluidigm’s commercialization infrastructure and organization toward further market adoption of the company’s products, particularly in the growing scientific community studying the human immune system.
“Colin’s impressive track record of metric-driven commercial growth on a global scale will help us deliver more of our products to customers who are transforming the treatment of human disease through a greater understanding of immune function,” said Linthwaite. “I am thrilled to welcome him to the team.”
“In addition, Colin’s demonstrated abilities in market expansion, business integration and management of teams in times of change make him ideally suited to lead commercial operations at Fluidigm during this exciting chapter of our growth.”
Prior to joining Fluidigm, McCracken was Vice President, Chromatography and Mass Spectrometry, EMEA, at Thermo Fisher Scientific. McCracken began his career in the medical devices space, later transitioning to a key account post with Bristol-Myers Squibb. Subsequently, he led major commercial operations in Europe for Invitrogen, Life Technologies and Thermo Fisher Scientific.
“Fluidigm is powering scientific progress in disease research that is leading to remarkable breakthroughs,” said McCracken. “I’m excited to have the opportunity to share this story with customers and expand the company’s global presence.”
McCracken is an honors graduate of the electrical and electronic engineering program at the University of Strathclyde in Glasgow.
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, and CyTOF are registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding growth in sales and market adoption of Fluidigm products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission, including the Fluidigm Quarterly Report on Form 10-Q for the quarter ended September 30, 2018. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Senior Director, Corporate Communications
650 243 6621
Vice President, Investor Relations
650 416 7423